Assessing Symptom Burden in Bladder Cancer: An Overview of Bladder Cancer Specific Health-Related Quality of Life Instruments
Bladder Cancer · 27.07.2016 · 2 (3) · 329-340
DOI: 10.3233/blc-160057 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bladder Cancer, online erschienen am 27.07.2016. Verfasst von Bernard J Danna und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, MD Anderson Cancer Center , Houston, TX, USA. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
A key component to monitoring and investigating patient QOL is through patient reported health related quality of life (HRQOL) outcome measures. Many instruments have been used to assess HRQOL in bladder cancer and each instrument varies in its development, validation, the context of its usage in the literature and its applicability to certain disease states.
Objective
In this review, we sought to summarize how clinicians and researchers should most appropriately utilize the available HRQOL instruments for bladder cancer.
Methods
We performed a comprehensive literature search of each instrument used in bladder cancer, paying particular attention to the outcomes assessed. We used these outcomes to group the available instruments into categories best reflecting their optimal usage by stage of disease.
Results
We found 5 instruments specific to bladder cancer, of which 3 are validated. Only one of the instruments (the EORTC-QLQ-NMIBC24) was involved in a randomized, prospective validation study. The most heavily used instruments are the EORTC-QLQ-BLM30 for muscle-invasive disease and the FACT-Bl which is used across all disease states. Of the 5 available instruments, 4 are automatically administered with general instruments, while the BCI lacks modularity, and requires co-administration with a generalized instrument.
Conclusion
There are multiple strong instruments for use in gauging HRQOL in bladder cancer patients. We have divided these instruments into three categories which optimize their usage: instruments for use following NMIBC treatments (EORTC-QLQ-NMIBC24), instruments for use following radical cystectomy (FACT-Bl-Cys and EORTC-QLQ-BLM30) and more inclusive instruments not limited by treatment modality (BCI and FACT-Bl).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, MD Anderson Cancer Center , Houston, TX, USA.
Zitieren
APA
Danna, B. J., Metcalfe, M. J., Wood, E. L., & Shah, J. B. (2016). Assessing Symptom Burden in Bladder Cancer: An Overview of Bladder Cancer Specific Health-Related Quality of Life Instruments. Bladder Cancer, 2(3), 329-340. https://doi.org/10.3233/blc-160057
Vancouver
Danna BJ, Metcalfe MJ, Wood EL, Shah JB. Assessing Symptom Burden in Bladder Cancer: An Overview of Bladder Cancer Specific Health-Related Quality of Life Instruments. Bladder Cancer. 2016;2(3):329-340. doi:10.3233/blc-160057
BibTeX
@article{Danna2016,
author = {Danna, Bernard J and Metcalfe, Michael J and Wood, Erika L and Shah, Jay B},
title = {Assessing Symptom Burden in Bladder Cancer: An Overview of Bladder Cancer Specific Health-Related Quality of Life Instruments},
journal = {Bladder Cancer},
year = {2016},
volume = {2},
number = {3},
pages = {329--340},
doi = {10.3233/blc-160057}
}
EUVIMED